Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 6/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.52 |
| ▸ | ACP3 | P15309 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.45 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
| ▸ | MMP16 | P51512 | 1/20 | 0.43 |
| ▸ | POLQ | O75417 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30428161 | 1.00 | AKR1C3 (0.52) | AKR1C3AKR1C2ACP3CNR2PTGS2 | |
| SCHEMBL27691016 | 0.87 | ACP3 (0.47) | AKR1C3AKR1C2ACP3CNR2P2RX7 | |
| SCHEMBL28969367 | 0.84 | ACP3 (0.45) | AKR1C3AKR1C2ACP3CNR2P2RX7 | |
| SCHEMBL4778256 | 0.84 | ACP3 (0.45) | AKR1C3AKR1C2ACP3CNR2CXCL8 | |
| SCHEMBL28187819 | 0.83 | MMP2 (0.47) | AKR1C3AKR1C2PTGS2CXCL8MMP1 | |
| SCHEMBL14661316 | 0.83 | P2RX7 (0.61) | AKR1C3AKR1C2CNR2PTGS2CXCL8 | |
| Hydrochloric Acid SCHEMBL6559016 | 0.82 | ACP3 (0.44) | AKR1C3AKR1C2ACP3CNR2CXCL8 | |
| SCHEMBL28821897 | 0.81 | ACP3 (0.53) | AKR1C3AKR1C2ACP3CNR2POLQ | |
| SCHEMBL3130946 | 0.81 | ACP3 (0.53) | AKR1C3AKR1C2ACP3CNR2POLQ | |
| SCHEMBL753073 | 0.81 | POLQ (0.47) | AKR1C3AKR1C2ACP3CNR2POLQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119486565-A | Perovskite precursor solution, perovskite solar cell, preparation method and photovoltaic module | 天合光能股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-117347515-A | Method for measuring residual quantity of cyflumetofen and three metabolites thereof in fresh tea leaves, black tea and tea soup | 中国农业科学院茶叶研究所 | 2024-01-05 | — | — | CN | disclosed |
| CN-116209433-A | Small molecule albumin binding agents | 俄勒冈健康科学大学 | 2023-06-02 | — | — | CN | disclosed |
| CN-109422749-B | Pyrimidinedione derivative for inhibiting monocarboxylic acid transporter | 重庆医药工业研究院有限责任公司 | 2023-01-24 | — | — | CN | disclosed |
| CN-112830879-A | Preparation method of cinacalcet hydrochloride | 北京泰德制药股份有限公司 | 2021-05-25 | — | — | CN | disclosed |
| WO-2019171277-A1 | CYLCOALKENYL DERIVATIVES USEFUL AS AGONISTS OF THE GPR120 AND /OR GPR40 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019171278-A1 | HETEROCYLCOALKENYL DERIVATIVES USEFUL AS AGONISTS OF THE GPR120 AND / OR GPR40 | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-12 | — | — | WO | disclosed |
| EP-2736888-A2 | 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013014204-A2 | 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-01-31 | — | — | WO | disclosed |
| US-20120071322-A1 | Substituted Pyridopyrazines with a Herbicidal Action | BASF SE (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120053171-A1 | Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2060570-B1 | Azabicyclo[3.1.0] hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-2401276-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | Eisai R&D Management Co., Ltd. (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20110251063-A1 | HETEROCYCLIC DIKETONE DERIVATIVES WITH HERBICIDAL ACTION | BASF SE (DE) | 2011-10-13 | — | — | US | disclosed |
| WO-2011064188-A1 | INSECTICIDAL METHODS USING NITROGEN-CONTAINING HETEROAROMATIC COMPOUNDS | BASF SE (DE) | 2011-06-03 | — | — | WO | disclosed |
| EP-1917013-B1 | USE OF AZABICYCLO HEXANE DERIVATIVES | GLAXO GROUP LTD (GB) | 2011-03-09 | — | — | EP | disclosed |
| US-20090036461-A1 | Use of Azabicyclo Hexane Derivatives | GLAXO GROUP LIMITED (GB) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053171-A1 | Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors | BACE1, APP, PSEN1 | AKR1C3 841/4885AKR1C2 1587/4885ACP3 4278/4885 |
| US-20090036461-A1 | Use of Azabicyclo Hexane Derivatives | ADH1C, PKD1, HTT | AKR1C3 839/4885AKR1C2 1077/4885ACP3 1396/4885 |
| US-20120071322-A1 | Substituted Pyridopyrazines with a Herbicidal Action | PLPBP, PNPO, PFAS | AKR1C3 1107/4885AKR1C2 1355/4885ACP3 3114/4885 |
| US-20110251063-A1 | HETEROCYCLIC DIKETONE DERIVATIVES WITH HERBICIDAL ACTION | DDT, KHK, HK1 | AKR1C3 268/4885AKR1C2 102/4885ACP3 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.